- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/655 - Somatostatines
Détention brevets de la classe C07K 14/655
Brevets de cette classe: 140
Historique des publications depuis 10 ans
|
13
|
9
|
8
|
12
|
7
|
3
|
10
|
2
|
2
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glytech, Inc. | 70 |
8 |
| BCN Peptides, S.A. | 33 |
5 |
| Braasch Biotech LLC | 8 |
5 |
| Immunwork Inc. | 25 |
5 |
| The Salk Institute for Biological Studies | 450 |
5 |
| Tel Hashomer Medical Research Infrastructure and Services Ltd. | 334 |
5 |
| Ipsen Pharma S.A.S. | 387 |
4 |
| University Hospital Basel | 16 |
4 |
| UCL Business Ltd | 567 |
4 |
| Novartis AG | 11221 |
3 |
| The Administrators of the Tulane Educational Fund | 386 |
3 |
| Ipsen Manufacturing Ireland Limited | 7 |
3 |
| Italfarmaco SpA | 141 |
3 |
| Adepthera LLC | 11 |
3 |
| Recordati AG | 48 |
3 |
| Taurus Biosciences, LLC | 8 |
3 |
| The Regents of the University of California | 19630 |
2 |
| Alchemia Limited | 3 |
2 |
| AmideBio, LLC | 15 |
2 |
| British Columbia Cancer Agency Branch | 196 |
2 |
| Autres propriétaires | 66 |